Austrian Breast & Colorectal Cancer Study Group

Science from the heart of Europe

Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients

Kerstin Wimmer, Monika Sachet, Cristiano Ramos, Sophie Frantal, Hanna Birnleitner, Christine Brostjan, Ruth Exner, Martin Filipits, Zsuzsanna Bago-Horvath, Margaretha Rudas, Rupert Bartsch, Michael Gnant, Christian F. Singer, Marija Balic, Daniel Egle, Rudolf Oehler & Florian Fitzal 

Journal of Experimental & Clinical Cancer Research volume 42, Article number: 300 (2023) 
Published: 14 November 2023
DOI: https://doi.org/10.1186/s13046-023-02876-x

---

ASO Visual Abstract: Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)

Walter P. Weber MD, Martin Heidinger MD, Stefanie Hayoz PhD, Zoltan Matrai MD, PhD, Christoph Tausch MD, Guido Henke MD, Daniel R. Zwahlen MD, Günther Gruber MD, Frank Zimmermann MD, Giacomo Montagna MD, MPH, Mariacarla Andreozzi PhD, Maite Goldschmidt MSc, Alexandra Schulz MSc, Andreas Mueller MD, Markus Ackerknecht PhD, Ekaterini Christina Tampaki MD, PhD, Vesna Bjelic-Radisic MD, Christian Kurzeder MD, Ákos Sávolt MD, PhD, Viktor Smanykó MD, Daniela Hagen MD, Dieter J. Müller MD, Michael Gnant MD, Sibylle Loibl MD, Florian Fitzal MD, Pagona Markellou MD, Inga Bekes MD, Daniel Egle MD, Jörg Heil MD & Michael Knauer MD, PhD 

Annals of Surgical Oncology (2023)
Published: 13 November 2023
DOI: https://doi.org/10.1245/s10434-023-14489-x

---

Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancer

Maximilian Marhold, Simon Udovica, Anna Halstead, Mona Hirdler, Muna Ferner, Kerstin Wimmer, Zsuzsanna Bago-Horvath, Ruth Exner, Florian Fitzal, Kathrin Strasser-Weippl, Tim Robinson & Rupert Bartsch

ONCOIMMUNOLOGY
Published online: 13 November  2023
DOI: https://doi.org/10.1080/2162402X.2023.2275846

---

Patient-reported outcomes in high-risk HR+/HER2- early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study

José Angel García-Sáenz, Frederik Marmé, Michael Untch, Hervé Bonnefoi, Sung-Bae Kim, Harry Bear, Nicole Mc Carthy, Karen Gelmon, Miguel Martin, Catherine M. Kelly, Toralf Reimer, Masakazu Toi, Ernest Law, Helen Bhattacharyya, Michael Gnant, Andreas Makris, Sabine Seiler, Nicole Burchardi, Valentina Nekljudova, Sibylle Loibl, Hope S. Rugo

European Journal of Cancer
Published: November 5^th, 2023
DOI: https://doi.org/10.1016/j.ejca.2023.113420

---

Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023.

Curigliano G, Burstein HJ, Gnant M, Loibl S, Cameron D, Regan MM, Denkert C, Poortmans P, Weber WP, Thürlimann B;

St Gallen Consensus Conference Panelists 2023.
Ann Oncol. 2023 Nov;34(11):970-986.
DOI: 10.1016/j.annonc.2023.08.017. Epub 2023 Sep 6.PMID: 37683978
https://pubmed.ncbi.nlm.nih.gov/37683978/

---

Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)

Lancet 2023; 401: 1277–92
DOI: https://doi.org/10.1016/S0140-6736(23)01082-6
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01082-6/fulltext
Open Access, Published: November 03, 2023

---

Impact of Imaging‑Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node‑Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC‑03, SAKK 23/16, IBCSG 57‑18, ABCSG‑53, GBG 101

Walter P. Weber, MD, Martin Heidinger, MD, Stefanie Hayoz, PhD , Zoltan Matrai, MD, PhD , Christoph Tausch, MD, Guido Henke, MD, Daniel R. Zwahlen, MD , Günther Gruber, MD , Frank Zimmermann, MD, Giacomo Montagna, MD, MPH, Mariacarla Andreozzi, PhD, Maite Goldschmid, Alexandra Schulz, Andreas Mueller, MD, Markus Ackerknecht, PhD, Ekaterini Christina Tampaki, MD, PhD, Vesna Bjelic‑Radisic, MD, Christian Kurzeder, MD, Ákos Sávolt, MD, PhD, Viktor Smanykó, MD, Daniela Hagen, MD, Dieter J. Müller, MD, Michael Gnant, MD, Sibylle Loibl, MD, Florian Fitzal, MD, Pagona Markellou, MD , Inga Bekes, MD , Daniel Egle, MD, Jörg Heil, MD, and Michael Knauer, MD, PhD

Annals of Surgical Oncology
DOI: 10.1245/s10434-023-14404-4
https://link.springer.com/article/10.1245/s10434-023-14404-4
Published 30 October 2023

---

Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Huober J, Weder P, Ribi K, Thürlimann B, Thery JC, Li Q, Vanlemmens L, Guiu S, Brain E, Grenier J, Dalenc F, Levy C, Savoye AM, Müller A, Membrez-Antonioli V, Gérard MA, Lemonnier J, Hawle H, Dietrich D, Boven E, Bonnefoi H;

Swiss Group for Clinical Cancer Research, Unicancer Breast Group, and Dutch Breast Cancer Research Group.

JAMA Oncol. 2023 Oct 1;9(10):1381-1389.
DOI: 10.1001/jamaoncol.2023.2909.PMID: 37561451
https://pubmed.ncbi.nlm.nih.gov/37561451/

---

Explaining risks and benefits of loco-regional treatments to patients.

Beltran-Bless AA, Kacerovsky-Strobl S, Gnant M.Breast.

2023 Oct;71:132-137. Epub 2023 Aug 22.PMID: 37634470 
DOI: 10.1016/j.breast.2023.08.006.
https://pubmed.ncbi.nlm.nih.gov/37634470/

---

LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases—a phase II study

Gudrun Piringer, Thomas Grienberger, Josef Thaler et al.

https://doi.org/10.3389/fonc.2023.1231600,
Frontiers in Oncology, 09.08.2023

---

Association of Axillary Dissection With Systemic Therapy in Patients With Clinically Node-Positive Breast Cancer

Walter P. Weber, MD; Zoltan Matrai, MD, PhD; Stefanie Hayoz, PhD; et al
von ABCSG-Seite als Co-Autoren vertreten sind F. Fitzal, M. Gnant, D. Egle

JAMA Surg. Published online July 19, 2023. doi:10.1001/jamasurg.2023.2840
https://jamanetwork.com/journals/jamasurgery/fullarticle/2807463

---

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors: existing and emerging differences.

Johnston S, Emde A, Barrios C, Srock S, Neven P, Martin M, Cameron D, Janni W, Gnant M.

JNCI Cancer Spectr. 2023 Jul 3;7(4):pkad045.
DOI: 10.1093/jncics/pkad045.PMID: 37369022 
https://pubmed.ncbi.nlm.nih.gov/37369022/

---

Third International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions).

Elfgen C, Leo C, Kubik-Huch RA, Muenst S, Schmidt N, Quinn C, McNally S, van Diest PJ, Mann RM, Bago-Horvath Z, Bernathova M, Regitnig P, Fuchsjäger M, Schwegler-Guggemos D, Maranta M, Zehbe S, Tausch C, Güth U, Fallenberg EM, Schrading S, Kothari A, Sonnenschein M, Kampmann G, Kulka J, Tille JC, Körner M, Decker T, Lax SF, Daniaux M, Bjelic-Radisic V, Kacerovsky-Strobl S, Condorelli R, Gnant M, Varga Z.Virchows

Arch. 2023 Jul;483(1):5-20.
DOI: 10.1007/s00428-023-03566-x. Epub 2023 Jun 17.PMID: 37330436 
https://pubmed.ncbi.nlm.nih.gov/37330436/

---

Managing a Long and Winding Road: Estrogen Receptor-Positive Breast Cancer.

Gnant M, Turner NC, Hernando C.

Am Soc Clin Oncol Educ Book. 2023 Jun;43:e390922.
DOI: 10.1200/EDBK_390922.PMID: 37319380 
https://pubmed.ncbi.nlm.nih.gov/37319380/

---

Uncertainties and controversies in axillary management of patients with breast cancer.

Weber WP, Davide Gentilini O, Morrow M, Montagna G, de Boniface J, Fitzal F, Wyld L, Rubio IT, Matrai Z, King TA, Saccilotto R, Galimberti V, Maggi N, Andreozzi M, Sacchini V, Castrezana López L, Loesch J, Schwab FD, Eller R, Heidinger M, Haug M, Kurzeder C, Di Micco R, Banys-Paluchowski M, Ditsch N, Harder Y, Paulinelli RR, Urban C, Benson J, Bjelic-Radisic V, Potter S, Knauer M, Thill M, Vrancken Peeters MJ, Kuemmel S, Heil J, Gulluoglu BM, Tausch C, Ganz-Blaettler U, Shaw J, Dubsky P, Poortmans P, Kaidar-Person O, Kühn T, Gnant M.

Cancer Treat Rev. 2023 Jun;117:102556.
DOI: 10.1016/j.ctrv.2023.102556. Epub 2023 Apr 23.PMID: 37126938
https://pubmed.ncbi.nlm.nih.gov/37126938/

---

Trends in use of neoadjuvant systemic therapy in patients with clinically node‑positive breast cancer in Europe: prospective TAXIS study (OPBC‑03, SAKK 23/16, IBCSG 57‑18, ABCSG‑53, GBG 101)

Tausch et al
von ABCSG-Seite als Co-Autoren vertreten sind F. Fitzal, M. Gnant, D. Egle, C. Hager. K. Reisenberger, C. Singer

>Breast Cancer Res Treat. 2023; 201(2): 215–225.

Published online 2023 Jun 25. doi: 10.1007/s10549-023-06999-9

---

Updated Austrian treatment algorithm for metastatic triple-negative breast cancer.

Bartsch R, Rinnerthaler G, Petru E, Egle D, Gnant M, Balic M, Sliwa T, Singer C.

Wien Klin Wochenschr. 2024 Jun;136(11-12):347-361.
DOI: 10.1007/s00508-023-02254-9. Epub 2023 Sep 8.PMID: 37682349 
https://pubmed.ncbi.nlm.nih.gov/37682349/

---

Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial

Georg Pfeiler, Dominik Hlauschek, Erica L. Mayer  et al

DOI: 10.1200/JCO.23.00126 Journal of Clinical Oncology
https://ascopubs.org/doi/abs/10.1200/JCO.23.00126

---

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
C Fesl, M Gnant, L Sölkner, G G Steger (Groups (lead investigators) contributing data)

Lancet 2023 Apr 15;401(10384):1277-1292.doi: 10.1016/S0140-6736(23)00285-4
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00285-4/fulltext

---

St. Gallen/Vienna 2023: Optimization of Treatment for Patients with Primary Breast Cancer – A Brief Summary of the Consensus Discussion.

Balic M, Thomssen C, Gnant M, Harbeck

N.Breast Care (Basel). 2023 Apr;18(3):213-222.
DOI: 10.1159/000530584. Epub 2023 Apr 7.PMID: 37383954 
https://pubmed.ncbi.nlm.nih.gov/37383954/

---

Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer

Ann H. Partridge, M.D., M.P.H., Samuel M. Niman, M.S., Monica Ruggeri, Fedro A. Peccatori, M.D., Ph.D., Hatem A. Azim, Jr., M.D., Ph.D., Marco Colleoni, M.D., Cristina Saura, M.D., Ph.D., Chikako Shimizu, M.D., Anna B. Sætersdal, M.D., Judith R. Kroep, M.D., Ph.D., Audrey Mailliez, M.D., Ellen Warner, M.D., et al., for the International Breast Cancer Study Group, and the POSITIVE Trial Collaborators†

The New England Journal of Medicine
N Engl J Med 2023; 388:1645-1656
DOI: 10.1056/NEJMoa2212856

IBCSG 48-14
https://www.nejm.org/doi/full/10.1056/NEJMoa2212856?query=featured_home

---

Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12

Ana-Alicia Beltran-Bless Mark J. Clemons Christian Fesl Richard Greil Gregory R. Pond Marija Balic Lisa Vandermeer Vesna Bjelic-Radisic Christian F. Singer Guenther G. Steger Ruth Helfgott Daniel Egle Lidija Sölkner Simon P. Gampenrieder Stephanie Kacerovsky-Strobl Christoph Suppan Magdalena Ritter Gabriel Rinnerthaler Georg Pfeiler Hannes Fohler Dominik Hlauschek John Hilton Michael Gnant

European Journal of Cancer 180 (2023), 108-116, DOI:
(https://doi.org/10.1016/j.ejca.2022.12.003)

---

Commentary on “Prognosis according to the timing of recurrence in breast cancer”.

Hlauschek D, Gnant M

Ann Surg Treat Res 2023;104:1-9 Annals of Surgical Treatment and Research
Published online: 2 January 2023
DOI: https://doi.org/10.4174/astr.2023.104.1.1